Pluto Bio, a pioneering company at the intersection of artificial intelligence and computational biology, is making waves with its intuitive platform designed to empower scientists.
The company recently announced a significant boost to its operations, having successfully raised $3.6 million in new funding. This investment round was led by new investor Kickstart, with continued strong support from existing backers Silverton Partners and a group of angel investors.
This fresh capital injection is earmarked to accelerate Pluto Bio’s growth and scale the adoption of its enterprise-grade platform among global pharmaceutical companies, further solidifying its position in the rapidly evolving drug discovery landscape.
Their core mission is to make complex, high-dimensional biological data more accessible and manageable, enabling researchers to accelerate the discovery of new therapies for pressing unmet medical needs.
Pluto Bio provides a “canvas for computational biology”—a secure, collaborative space where scientists can explore vast datasets, execute sophisticated bioinformatics pipelines, and create publication-ready visuals, all without needing to write a single line of code, thereby significantly speeding up the research process.
The enthusiasm for Pluto Bio‘s approach is palpable among its investors. “AI is transforming how we interrogate biology,” commented Dalton Wright, General Partner at Kickstart.
“What impressed us about Pluto is how it puts the power of LLMs into the hands of domain expert scientists – biologists, translational researchers, and discovery teams – by giving them an instantly intuitive interface for expressing scientific questions faster and in a way that increases scientific rigor and reproducibility.”
Dr. Rani Powers, Founder and CEO of Pluto Bio, added, “With this funding, we’re fueling our mission to make high-dimensional biological data accessible to the people who deeply understand the underlying biology and unmet therapeutic needs.”
This new funding will specifically support the continued development of Pluto’s AI agents, expand integrations, build out commercial roles, and accelerate deployment across therapeutic areas.
If you click on a link and make a purchase we may receive a small commission. Learn more. All content on this site is provided with no warranties, express or implied. Use any information at your own risk. Privacy Policy.
Discover more from BITVoxy
Subscribe to get the latest posts sent to your email.
